30 results about "Pyroglutamic acid" patented technology

The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.

The invention belongs to the technical field of recycling of waste lithium batteries, and particularly relates to an adsorption carrier for recycling of metal in waste lithium ion batteries and a preparation method thereof. The preparation method comprises the following steps of (1) mixing chitosan and pyroglutamic acid, adding water to dissolve, adding an acid solution, adjusting the pH (potential of hydrogen) value to 4.0 to 5.0, heating, warming and stirring; adding manganese dioxide and thiocarbazide, reacting for 2 to 3h under the heat preservation condition, centrifuging and filtering, sending filtering residue into a freeze-drying machine, drying the solid, and crushing by a superfine crusher, so as to obtain a micropowder; (2) dissolving the micropowder and soluble metal salt, dispersing into an acetic acid water solution, and stirring to react, so as to obtain a precursor of the adsorption carrier; (3) impregnating the precursor of the adsorption carrier by the acid solution,so as to obtain the adsorption carrier. The adsorption carrier has the advantages that the metal is recycled from the waste lithium ion batteries in a targeted way; the adsorption carrier for the recycling of metal ions can be repeatedly utilized, so as to effectively reduce the recycling cost of the metal.

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

The invention provides antibodies or antigen binding fragments thereof that bind to 3pE Aβ and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

The invention discloses a method for treating a last monosodium glutamate mother liquor, which comprises the steps: removing sulfate radicals in the last monosodium glutamate mother liquor containing sodium pyroglutamate impurities through barium salt first, then using ionic membrane caustic soda to hydrolyze to ensure that sodium pyroglutamate is unlinked and transformed into sodium glutamate, precipitating a large amount of flocculent colloid at the same time, then removing precipitated colloid protein, salt precipitations and the like through two plate-and-frame filtrations, sending filtrate into an inorganic membrane for microfiltration separation to further remove impurities such as solid protein to obtain clear permeate liquid, sending the permeate liquid into a nanofilration membrane separation system to remove impurities such as soluble colloid, protein, residual sugar and pigment to obtain high-quality feed liquid, and re-sending the feed liquid into a monosodium glutamate production cycle chain to produce monosodium glutamate. The method removes impurities such as sulfate, metallic ions (such as calcium, magnesium, iron and the like), colloid, protein, residual sugar and pigment in the last monosodium glutamate mother liquor, improves the quality of the hydrolysis of the last monosodium glutamate mother liquor, replaces acid hydrolysis, reduces the consumption of a decoloring agent and the discharge amount of wastewater, and ensures that the production cost is greatly reduced.

The invention discloses an agricultural composition containing dextran, which comprises effective components A and B, the A component is dextran, and the B component is amino oligosaccharin and chitosan , a kind of mushroom polysaccharide. The agricultural composition is used in combination with an auxiliary agent package, and the effective component of the auxiliary agent package is a compound of diosgenin and L-pyroglutamic acid. In terms of mass ratio, the diosgenin and L-pyroglutamic acid ‑The mass ratio of pyroglutamic acid is 3:2. Within a certain proportion range, the agricultural composition has excellent control effects on tobacco mosaic virus disease, tomato virus disease and cucumber mosaic virus disease, and can promote crop yield increase.

The invention relates to a method to monitor treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE) : total concentration of MCP-1 within a biological sample as a biomarker and further concerns a novel method to determine the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. The invention also provides a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor.

The invention discloses a synthetic method of an avibactam intermediate (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate. N-protective group-L-pyroglutamate (SM) is taken as an initial raw material, and the (2S,5S)-N-protective group-5-hydroxy-2-piperidine formate is obtained through six steps of reactions including trimethyl sulfoxide iodide recarburization ring opening, halogenation under the action of acid, high-selectivity reduction, lactone ring formation under the catalysis of acid, piperidine ring closing under the action of alkali and hydrolysis. The synthetic method is mild in reaction conditions, simple and convenient to operate, easy in impurity control and stable in yield. The used reagents are low in price, the cost is effectively reduced, and the method is environment-friendly and suitable for industrial production.

The invention belongs to the field of analytical chemistry and clinical medicine, and discloses gluconolactone and pyroglutamic acid as auxiliary diagnostic markers for macrosomia and their application. The markers are small molecule gluconolactone and pyroglutamic acid in serum metabolism during pregnancy . The marker is detected by UPLC‑Q exact MS method, which has good sensitivity and specificity, can be used for early diagnosis or monitoring of macrosomia, and has good clinical application and promotion value.

A polypeptide having the general amino acid sequenceZ1IX2RWX5X6KX8PX10X11SZ3,whereinX2=V, M or L,X5=S or T,X6=K or R,X8=V, M, L or F,X10=Q or C,X11=V, M or F;Z1=0, Z2, or pyro glutamate, wherein Z2 is a modification of the amino group of the N-terminal amino acid having the structure —NR2R3 wherein R2 and / or R3 are independently from each other H or an acyl, alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group;Z3=0, or Z4, wherein Z4 is a modification of the carboxyl group of the C-terminal amino acid having the structure —C(O)—O—R1 or —C(O)—NR2R3, wherein R1 is an alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group; and R2 and R3 are defined as above.

The invention relates to pidotimod, in particular to a process for synthesizing and purifying pidotimod with high chiral purity. The synthesis and purification process is to add L-thioproline ethyl ester hydrochloride and L-pyroglutamic acid to the corresponding single crystal cultivation solution respectively to carry out single crystal cultivation, after condensation, hydrolysis, acidification, Chiral purification to obtain pidotimod with high chiral purity. In the present invention, L-thioproline containing D-thioproline and L-pyroglutamic acid containing D-pyroglutamic acid are cultivated as single crystals to achieve the purpose of separating chiral isomers, and then All chiral isomers present are completely removed by a chiral column. The invention overcomes the defect that the existing technology cannot completely remove the chiral impurities, and finds a simple, effective, safe and environment-friendly method.

The invention discloses a synthesis method of an Avibactam intermediate, and belongs to the technical field of the medicine chemical synthesis. The synthesis method comprises the following steps: reacting pyroglutamate containing an amino protecting group with trimethylsulfoxonium iodide in a reaction solvent under the effect of the carbonate to obtain the Avibactam intermediate. The problems thata strong alkali process method in the prior art is large in potential safety hazard, relatively difficult in process control and high in impurity content are avoided, and the synthesis method disclosed by the invention is mild in reaction condition, simple in operation, high in process operability security, high in yield, high in product purity and suitable for the industrial production.

The invention provides antibodies or antigen binding fragments thereof that bind to 3pE Aβ and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (QC) with E45Q mutation, so as to autonomously produce a target protein having a N-terminal pyroglutamate (pGlu) residue in a host cell. The first fusion protein is composed of a maltose binding protein (MBP) and a tobacco etch virus protease (TEVP); and the second fusion protein includes in sequence, a thioredoxin, a S-tag, a linker having a TEVP recognition site therein, a target protein, and a (His)-6-tag. The second fusion protein is cleaved by the TEVP that is expressed by the first fusion protein, and then catalyzed by QC with E45Q mutation so as to autonomously produce the target protein having a N-terminal pGlu residue in the host cell.

The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt

The invention discloses a compound represented by formula I. The invention also discloses the use of the compound represented by formula I in preparing bioluminescent probes, especially bioluminescent probes for detecting pyroglutamate aminopeptidase. The probe provided by the invention shows good sensitivity, selectivity and biocompatibility to the target product. The probe provided by the invention can not only detect pyroglutamate aminopeptidase with good linearity and semi-quantitatively in an in vitro environment, but also has the ability to visually detect endogenous pyroglutamate aminopeptidase at the living level. The preparation method of the probe of the present invention is simple, high in yield, low in cost, high in efficiency, strong in specificity, fast and sensitive in substrate detection, and can realize qualitative and semi-quantitative detection and analysis of pyroglutamate aminopeptide at the same time Enzymes are easy to popularize and apply.

The present invention discloses novel application of n-butanol-2-O-(L-pyroglutamate-N-6-)-alpha-D-fructofuranoside, including application in Alzheimer's disease (AD), application in neuronal cell proliferation, application in improvement of learning and memory and cognitive ability and application in inhibiting the activity of AchE, increasing the content of ChAT and Ach. L-pyroglutamate alpha inthe present invention can bind to a muscarinic receptor M3 due to the spatial configuration of the L-pyroglutamate alpha, after the L-pyroglutamate alpha binds to the muscarinic receptor M3, the Ach in the brain of an AD patient is retained, so that the content of Ach is increased, while L-pyroglutamate beta cannot bind to the muscarinic receptor M3, which also shows that L-pyroglutamate alpha hasexcellent AD resisting function. The present invention provides an effective basis for L-pyroglutamate alpha in resisting AD through molecular biology, thereby providing new ideas for the developmentof anti-AD drugs.

The invention discloses a preparation method of L-pyroglutamic acid, which comprises (1) adding glutamic acid or hydrolyzed recycled materials into a reaction kettle and heating, controlling the temperature at 145-150°C, stirring intermittently, and dissolving completely to obtain a feed liquid , add purified water to the feed liquid, crystallize and centrifuge multiple times, combine the crystallized products to obtain solid A, and combine the mother liquor to obtain liquid 1; (2) heat solid A in a solvent to 35-45°C, dissolve completely and send Put it into the decolorization tank, raise the temperature to 65-75°C, then add activated carbon, after heat preservation and adsorption, filter to obtain the decolorization liquid, cool and crystallize the decolorization liquid, centrifuge to obtain the wet product, and use the crystallization mother liquor for many times, concentrate and recrystallize to obtain Solid B and liquid 2; (3) Vacuum-dry the wet product, the temperature of the vacuum-drying is 80-85°C, after the drying is completed, the temperature is lowered and cooled, and the L-pyroglutamic acid is obtained after detection. The production process is simple, the reaction conditions are mild, the product yield and purity are high, no polluting waste is discharged, and it is convenient for large-scale continuous production.